-the gene at the moment in non-small cell lung cancer.
作者信息
Thu Kelsie L, Yoon Ju-Yoon
机构信息
Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.
Keenan Research Centre for Biomedical Sciences, St. Michael's Hospital of Unity Health Toronto, Toronto, Canada.
出版信息
Transl Lung Cancer Res. 2024 Mar 29;13(3):699-705. doi: 10.21037/tlcr-23-853. Epub 2024 Mar 15.
Abstract
摘要
相似文献
1
-the gene at the moment in non-small cell lung cancer.目前非小细胞肺癌中的该基因。
Transl Lung Cancer Res. 2024 Mar 29;13(3):699-705. doi: 10.21037/tlcr-23-853. Epub 2024 Mar 15.
2
Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells.聚 ADP 核糖聚合酶与共济失调毛细血管扩张突变/ Rad3 相关抑制物靶向共济失调毛细血管扩张突变缺陷型肺癌细胞。
Br J Cancer. 2019 Oct;121(7):600-610. doi: 10.1038/s41416-019-0565-8. Epub 2019 Sep 4.
3
Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.肿瘤蛋白 p53 和共济失调毛细血管扩张突变与非小细胞肺癌患者免疫检查点抑制剂反应和死亡率的关联。
JAMA Netw Open. 2019 Sep 4;2(9):e1911895. doi: 10.1001/jamanetworkopen.2019.11895.
4
Somatic and germline ATM variants in non-small-cell lung cancer: Therapeutic implications.非小细胞肺癌中的体细和种系 ATM 变异体：治疗意义。
Crit Rev Oncol Hematol. 2023 Aug;188:104058. doi: 10.1016/j.critrevonc.2023.104058. Epub 2023 Jun 19.
5
ATM protein is deficient in over 40% of lung adenocarcinomas.超过40%的肺腺癌中存在ATM蛋白缺陷。
Oncotarget. 2016 Sep 6;7(36):57714-57725. doi: 10.18632/oncotarget.9757.
6
[TRIP13 Enhances Radioresistance of Lung Adenocarcinoma Cells
through the Homologous Recombination Pathway].[TRIP13通过同源重组途径增强肺腺癌细胞的放射抗性]
Zhongguo Fei Ai Za Zhi. 2024 Jan 20;27(1):1-12. doi: 10.3779/j.issn.1009-3419.2023.106.27.
7
The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo.口服活性且具有生物利用度的 ATR 激酶抑制剂 AZD6738 可增强顺铂的抗肿瘤作用，以在体内解决 ATM 缺陷型非小细胞肺癌问题。
Oncotarget. 2015 Dec 29;6(42):44289-305. doi: 10.18632/oncotarget.6247.
8
Novel ATM Gene c.5644 C > T (p.Arg1882*) Variant Detected in a Patient with Pancreatic Adenocarcinoma and Two Primary Non-Small Cell Lung Adenocarcinomas: A Case Report.在一名胰腺腺癌合并两原发性非小细胞肺腺癌患者中检测到新型ATM基因c.5644 C>T（p.Arg1882*）变异：病例报告
Diseases. 2022 Dec 1;10(4):115. doi: 10.3390/diseases10040115.
9
Bilateral diffuse metastases in advanced lung adenocarcinoma harboring EGFR mutations was associated with a favorable prognosis to EGFR-TKIs.晚期肺腺癌伴 EGFR 突变的双侧弥漫性转移与 EGFR-TKIs 的良好预后相关。
Int J Cancer. 2024 Jun 1;154(11):1979-1986. doi: 10.1002/ijc.34878. Epub 2024 Feb 14.
10
The role of the ataxia telangiectasia mutated gene in lung cancer: recent advances in research.共济失调毛细血管扩张突变基因在肺癌中的作用：研究新进展。
Ther Adv Respir Dis. 2017 Sep;11(9):375-380. doi: 10.1177/1753465817725716. Epub 2017 Aug 21.
引用本文的文献
1
The Prognostic and Predictive Roles of Ataxia-Telangiectasia Mutated (ATM) Expression in Patients with Metastatic Non-Small-Cell Lung Cancer Receiving Pembrolizumab Monotherapy Alone or in Combination with Chemotherapy.共济失调毛细血管扩张症突变基因（ATM）表达在接受帕博利珠单抗单药治疗或联合化疗的转移性非小细胞肺癌患者中的预后及预测作用
Diagnostics (Basel). 2025 Apr 21;15(8):1048. doi: 10.3390/diagnostics15081048.
本文引用的文献
1
Rate of Pathogenic Germline Variants in Patients With Lung Cancer.肺癌患者种系致病性变异的发生率。
JCO Precis Oncol. 2023 Sep;7:e2300190. doi: 10.1200/PO.23.00190.
2
ATM Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC.ATM 突变与 NSCLC 中独特的共突变模式和治疗弱点相关。
Clin Cancer Res. 2023 Dec 1;29(23):4958-4972. doi: 10.1158/1078-0432.CCR-23-1122.
3
Potential pathogenic germline variant reporting from tumor comprehensive genomic profiling complements classic approaches to germline testing.肿瘤综合基因组分析报告的潜在致病性种系变异补充了种系检测的经典方法。
NPJ Precis Oncol. 2023 Aug 11;7(1):76. doi: 10.1038/s41698-023-00429-1.
4
Homologous recombination pathway gene variants identified by tumor-only sequencing assays in lung carcinoma patients.通过仅对肿瘤进行测序分析在肺癌患者中鉴定出的同源重组途径基因变异。
Transl Lung Cancer Res. 2023 Jun 30;12(6):1236-1244. doi: 10.21037/tlcr-22-749. Epub 2023 Jun 8.
5
Somatic and germline ATM variants in non-small-cell lung cancer: Therapeutic implications.非小细胞肺癌中的体细和种系 ATM 变异体：治疗意义。
Crit Rev Oncol Hematol. 2023 Aug;188:104058. doi: 10.1016/j.critrevonc.2023.104058. Epub 2023 Jun 19.
6
Current practice of genomic profiling of patients with advanced solid tumours in Italy: the Italian Register of Actionable Mutations (RATIONAL) study.意大利晚期实体瘤患者基因组分析的现行实践：意大利可操作突变登记（RATIONAL）研究。
Eur J Cancer. 2023 Jul;187:174-184. doi: 10.1016/j.ejca.2023.03.027. Epub 2023 Mar 30.
7
Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non-Small Cell Lung Cancer.非小细胞肺癌中 ATM 突变的临床病理、基因组和免疫表型全景。
Clin Cancer Res. 2023 Jul 5;29(13):2540-2550. doi: 10.1158/1078-0432.CCR-22-3413.
8
Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer.基因组和转录组分析晚期非小细胞肺癌的检查点阻断反应。
Nat Genet. 2023 May;55(5):807-819. doi: 10.1038/s41588-023-01355-5. Epub 2023 Apr 6.
9
Mutational landscape of homologous recombination-related genes in small-cell lung cancer.小细胞肺癌中同源重组相关基因的突变景观。
Cancer Med. 2023 Feb;12(4):4486-4495. doi: 10.1002/cam4.5148. Epub 2022 Aug 26.
10
Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer.胚系致病性变异影响晚期肺癌的临床病理。
Cancer Epidemiol Biomarkers Prev. 2022 Jul 1;31(7):1450-1459. doi: 10.1158/1055-9965.EPI-21-1287.
Zotero 插件